Top

Drugs

Published in:

01-06-2004 | Therapy in Practice

Mucosal and Systemic Fungal Infections in Patients with AIDS

Prophylaxis and Treatment

Author: Dr Markus Ruhnke, Med

Published in: Drugs | Issue 11/2004

Abstract

In countries where highly active antiretroviral therapy (HAART) is widely available, a decrease in the incidence of fungal infections has been observed in the last 5 years compared with countries that cannot afford this treatment. Even refractory fungal infections may be controlled when HAART is given to patients, and end-stage AIDS infections, such as aspergillosis, are now only infrequently seen. In contrast, fungal infections in certain regions, such as penicilliosis in Southeast Asia or cryptococcosis in Sub-Saharan Africa, are a growing problem.

Antifungal therapy for documented infections has not changed very much during recent years; however, new drugs such as caspofungin and voriconazole may be more effective in the treatment of opportunistic fungal infections, in particular, those involving resistant organisms.

Secondary antifungal prophylaxis for many opportunistic pathogens can now be temporarily or even permanently discontinued in many HIV-positive patients who have a marked improvement in immune function parameters, such as CD4+ cell counts, after initiation of HAART. The link between effective virustatic control of HIV infection and a decreasing incidence of fungal infections has been recognised; and so, despite the availability of very effective new antifungal drugs, the cornerstone of treatment and prevention of opportunistic fungal infections in patients with HIV infection is effective antiretroviral therapy including protease inhibitors.

The use of trade names is for product identification purposes only and does not imply endorsement.

From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993; 269: 729–30CrossRef

Sirisanthana T, Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis 1998 Jul–Sep; 3(1): 48–53PubMedCrossRef

Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14: 871–4PubMedCrossRef

Heller HM, Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS 1991; 5: 1243–6PubMedCrossRef

Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 654–62PubMedCrossRef

Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases: French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993; 95: 177–87PubMedCrossRef

Minamoto GY, Barlam TF, Vander-Els NJ. Invasive aspergillosis in patients with AIDS. Clin Infect Dis 1992; 14: 66–74PubMedCrossRef

Mylonakis E, Barlam TF, Flanigan T, et al. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998 Jul; 114(1): 251–62PubMedCrossRef

Cuadrado LM, Guerrero A, Garcia-Asenjo JA, et al. Cerebral mucormycosis in two cases of acquired immunodeficiency syndrome. Arch Neurol 1988; 45: 109–11PubMedCrossRef

10.

Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease: Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 710–8PubMedCrossRef

11.

Barchiesi F, Morbiducci V, Ancarani F, et al. Trichosporon beigelii fungaemia in an AIDS patient [letter]. AIDS 1993; 7: 139–40PubMedCrossRef

12.

Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416–29PubMedCrossRef

13.

Powles MA, Liberator P, Anderson J, et al. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystiscarinii. Antimicrob Agents Chemother 1998; 42: 1985–9PubMed

14.

Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis cariniipneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425–31PubMedCrossRef

15.

Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1993; 327(24): 477–80

16.

Greenspan D, Greenspan JS. HIV-related oral disease. Lancet 1996 Sep 14; 348(9029): 729–33PubMedCrossRef

17.

Schmidt-Westhausen A, Schiller RA, Pohle HD, et al. Oral Candida and enterobacteriaceae in HIV-1 infection: correlation with clinical candidiasis and antimycotic therapy. J Oral Pathol Med 1991; 20: 467–72PubMed

18.

Dodd CL, Greenspan D, Katz MH, et al. Oral candidiasis in HIV infection: pseudomembranous and erythematous candidiasis show similar rates of progression to AIDS. AIDS 1991; 5: 1339–43PubMedCrossRef

19.

Shiboski CH, Wilson CM, Greenspan D, et al. HIV-related oral manifestations among adolescents in a multicenter cohort study. J Adolesc Health 2001 Sep; 29 (3 Suppl.): 109–14

20.

Imam N, Carpenter CC, Mayer KH, et al. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 1990; 89: 142–6PubMedCrossRef

21.

Sobel JD. Gynecologic infections in human immunodeficiency virus-infected women. Clin Infect Dis 2000; 31: 1225–33PubMedCrossRef

22.

USPHS/IDSA. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 Suppl. 1: S29–65CrossRef

23.

Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100mg oral fluconazole daily. Arch Intern Med 1991; 151: 2458–64PubMedCrossRef

24.

Parente F, Ardizzone S, Cernuschi M, et al. Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. Am J Gastroenterol 1994; 89: 416–20PubMed

25.

Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997; 126: 689–96

26.

Just-Nübling G, Gentschew G, Meissner K, et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur J Clin Microbiol Infect Dis 1991; 10: 917–21PubMedCrossRef

27.

Revankar SG, Kirkpatrick WR, McAtee RK, et al. A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. Am J Med 1998; 105: 7–11PubMedCrossRef

28.

Linpiyawan R, Jittreprasert K, Sivayathorn A. Clinical trial: clotrimazole troche vs itraconazole oral solution in the treatment of oral candidosis in AIDS patients. Int J Dermatol 2000; 39: 859–61PubMedCrossRef

29.

Blatchford NR. Treatment of oral candidosis with itraconazole: a review. J Am Acad Dermatol 1990; 23(3): 565–7PubMedCrossRef

30.

Pons V, Greenspan D, Debruin M. Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches: the Multicenter Study Group. J Acquir Immune Defic Syndr 1993; 6: 1311–6PubMed

31.

Pons V, Greenspan D, Lozada-Nur F, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997; 24: 1204–7PubMedCrossRef

32.

Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992; 116: 847–53PubMed

33.

Dismukes WE, Bradsher Jr RW, Cloud GA, et al. Itraconazole therapy for blastomycosis and histoplasmosis: NIAID Mycoses Study Group. Am J Med 1992 Nov; 93(5): 489–97PubMedCrossRef

34.

Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candidaesophagitis in AIDS: a randomized trial. Ann Intern Med 1992; 117: 655–60PubMed

35.

Barbaro G, Barbarini G, Di Lorenzo G. Fluconazole vs itraconazole-flucytosine association in the treatment of esophageal candidiasis in AIDS patients: a double-blind, multicenter placebo-controlled study. The Candida Esophagitis Multicenter Italian Study (CEMIS) Group. Chest 1996; 110: 1507–14PubMedCrossRef

36.

Barbaro G, Barbarini G, Calderon W, et al. Fluconazole versus itraconazole for Candida esophagitis in acquired immunodeficiency syndrome: Candida Esophagitis. Gastroenterology 1996; 111: 1169–77PubMedCrossRef

37.

Mel Wilcox C, Darouiche RO, Laine L, et al. A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 1997; 176: 227–32CrossRef

38.

Arathoon EG, Gotuzzo E, Noriega LM, et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin b for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451–7PubMedCrossRef

39.

Ally R, Schürmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447–54PubMedCrossRef

40.

Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000 Nov 7; 133(9): 676–86

41.

Menichetti F, Fiorio M, Tosti A, et al. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22: 838–40PubMedCrossRef

42.

Larsen RA, Leal MA, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990; 113: 183–7PubMed

43.

Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis: the NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326: 83–9PubMedCrossRef

44.

van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome: National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337: 15–21PubMedCrossRef

45.

Chotmongkol V, Sukeepaisarncharoen W, Thavornpitak Y. Comparison of amphotericin B, flucytosine and itraconazole with amphotericin B and flucytosine in the treatment of cryptococcal meningitis in AIDS. J Med Assoc Thai 1997; 80: 416–25PubMed

46.

Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11: 1463–71PubMedCrossRef

47.

Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome: National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997 Sep; 103(3): 223–32PubMedCrossRef

48.

Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trial Group. Am J Med 1995; 98: 336–42PubMedCrossRef

49.

Wheat LJ, Cloud G, Johnson PC, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother 2001; 45: 2354–7PubMedCrossRef

50.

Sirisanthana T, Supparatpinyo K, Perriens J, et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium mameffeiinfection in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26: 1107–10PubMedCrossRef

51.

Goa KL, Barradell LB. Fluconazole: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995; 50: 658–90PubMedCrossRef

52.

Chave JP, Cajot A, Bille J, et al. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study [letter]. J Infect Dis 1989; 159: 806–7PubMedCrossRef

53.

Graybill JR, Vazquez F, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998; 104: 33–9PubMedCrossRef

54.

Phillips P, De-Beule K, Frechette G, et al. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368–73PubMedCrossRef

55.

Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997; 50: 477–80PubMedCrossRef

56.

Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38(2): 161–89PubMedCrossRef

57.

Sollima S, Corbellino M, Cicconi P, et al. Resolution of multidrug-refractory oesophageal candidiasis in an AIDS patient after treatment with caspofungin. AIDS 2002; 16: 1303–4PubMedCrossRef

58.

Hegener P, Troke PF, Fätkenheuer G, et al. Treatment of fluconazole resistant candidosis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227–41PubMed

59.

Fichtenbaum CJ, Powderly WG. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 26: 556–65PubMedCrossRef

60.

Barbaro G, Barbarini G, Di-Lorenzo G. Fluconazole compared with itraconazole in the treatment of esophageal candidiasis in AIDS patients: a double-blind, randomized, controlled clinical study. Scand J Infect Dis 1995; 27: 613–7PubMedCrossRef

61.

Cartledge JD, Midgley J, Youle M, et al. Itraconazole cyclodextrin solution: effective treatment for HIV-related candidosis unresponsive to other azole therapy [letter]. J Antimicrob Chemother 1994; 33: 1071–3PubMedCrossRef

62.

Vuffray A, Durussel C, Boerlin P, et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients [letter]. AIDS 1994; 8: 708–9PubMedCrossRef

63.

Patton LL, McKaig R, Strauss R, et al. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299–304PubMedCrossRef

64.

Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candidaalbicansassociated with trends toward reduced rates of carriage of fluconazole-resistant C. albicansin human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27: 1291–4PubMedCrossRef

65.

Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000; 14: 979–85PubMedCrossRef

66.

San-Andres FJ, Rubio R, Castilla J, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989–1997. Clin Infect Dis 2003; 36: 1177–85PubMedCrossRef

67.

Zingman BS. Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir [letter]. N Engl J Med 1996; 334: 1674–5PubMedCrossRef

68.

Valdez H, Gripshover BM, Salata RA, et al. Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy [letter]. AIDS 1998; 12: 538PubMed

69.

Revankar SG, Sanche SE, Dib OP, et al. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12: 2511–3PubMed

70.

Gripshover BM, Valdez H, Salata RA, et al. Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors. AIDS 1998; 12: 2513–4PubMed

71.

Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002 Dec 15; 35(12): el28–33CrossRef

72.

Shelburne III SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003 Apr–Jun; 5(2): 67–79PubMed

73.

Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome: the NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992; 326: 793–8PubMedCrossRef

74.

van Eiden LJ, Walenkamp AM, Lipovsky MM, et al. Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy. AIDS 2000; 14: 2787–8CrossRef

75.

Martinez E. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy. AIDS 2000; 14: 2615–7PubMedCrossRef

76.

Nwokolo NC, Fisher M, Gazzard BG, et al. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001; 15: 1438–9PubMedCrossRef

77.

Nelson MR, Fisher M, Cartledge JD, et al. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 1994; 8: 651–4PubMedCrossRef

78.

Hecht FM, Wheat J, Korzun AH, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 100–7PubMedCrossRef

79.

Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome: the National Institute of Allergy and Infectious Diseases Clinical Trials and Mycoses Study Group Collaborators. Ann Intern Med 1993; 118: 610–6PubMed

80.

Norris S, Wheat J, McKinsey D, et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med 1994; 96: 504–8PubMedCrossRef

81.

Supparatpinyo K, Perriens J, Nelson KE, et al. A controlled trial of itraconazole to prevent relapse of Penicilliummameffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 1998; 339: 1739–43PubMedCrossRef

82.

Chariyalertsak S, Supparatpinyo K, Sirisanthana T, et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002 Jan 15; 34(2): 277–84PubMedCrossRef

83.

McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28: 1049–56

84.

Laurenson IF, Trevett AJ, Lalloo DG, et al. Meningitis caused by Cryptococcusneoformansvar. gattiiand var. neoformans in Papua New Guinea. Trans R Soc Trop Med Hyg 1996; 90: 57–60PubMedCrossRef

85.

Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999 Jan; 28(1): 82–92PubMedCrossRef

86.

Just-Nübling G. Therapy of candidiasis and cryptococcosis in AIDS [in German]. Mycoses 1994; 37 Suppl. 2: 56–63

87.

Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44: 1544–8PubMedCrossRef

88.

Viviani MA, Rizzardini G, Tortorano AM, et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 1994; 22: 137–42PubMedCrossRef

89.

Bartizal K, Gill CJ, Abruzzo GK, et al. Invitropreclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326–32PubMed

90.

Pfaller MA, Zhang J, Messer SA, et al. Invitroactivities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 1999 Jan; 43(1): 169–71PubMedCrossRef

91.

Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–31PubMedCrossRef

92.

Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis 2003 Mar 15; 36(6): 789–94PubMedCrossRef

93.

Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36: 1329–1PubMedCrossRef

94.

Lortholary O, Droz C, Sitbon K, et al. Long-term outcome of HIV-associated cryptococcosis (CC) at the time of HAART: results of the Multicenter Cohort, ‘Cryptostop’ [abstract no. M-1752]. In: 43rd ICAAC Abstracts, American Society for Microbiology; 2003 Sep 14–17; Chicago, 475

95.

Coccidioidomycosis: Arizona, 1990–1995. MMWR Morb Mortal Wkly Rep 1996; 45: 1069–73

96.

Jones JL, Fleming PL, Ciesielski CA, et al. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis 1995; 171: 961–6PubMedCrossRef

97.

Fish DG, Ampel NM, Galgiani JN, et al. Coccidioidomycosis during human immunodeficiency virus infection: a review of 77 patients. Medicine (Baltimore) 1990 Nov; 69(6): 384–91

98.

Mathew G, Smedema M, Wheat LJ, et al. Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS. Mycoses 2003 Feb; 46(1–2): 42–4PubMedCrossRef

99.

Diaz M, Negroni R, Montero-Gei F, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host: Pan-American Study Group. Clin Infect Dis 1992; 14 Suppl. 1: S68-76

100.

Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis 2000; 30: 658–61PubMedCrossRef

101.

Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis: the NIAID-Mycoses Study Group. Ann Intern Med 1993 Jul 1; 119(1): 28–35PubMed

102.

Li RK, Ciblak MA, Nordoff N, et al. Invitroactivities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioidesimmitis, and Histoplasma capsulatum. Antimicrob Agents Chemother 2000; 44: 1734–6PubMedCrossRef

103.

Gonzalez GM, Tijerina R, Najvar LK, et al. Correlation between antifungal susceptibilities of Coccidioidesimmitisin vitroand antifungal treatment with caspofungin in a mouse model. Antimicrob Agents Chemother 2001; 45: 1854–9PubMedCrossRef

104.

Cortez KJ, Walsh TJ, Bennett JE. Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003; 36: 1619–22PubMedCrossRef

105.

Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev 1995 Jan; 8(1): 146–59PubMed

106.

Marques SA, Robles AM, Tortorano AM, et al. Mycoses associated with AIDS in the Third World. Med Mycol 2000; 38 Suppl. 1: 269–79

107.

Hajjeh RA, Pappas PG, Henderson H, et al. Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons. Clin Infect Dis 2001; 32: 1215PubMedCrossRef

108.

Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000; 30: 688–95PubMedCrossRef

109.

McKinsey DS, Gupta MR, Driks MR, et al. Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy. Am J Med 1992; 92: 225–7PubMedCrossRef

110.

Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant 2000 Aug; 14(4): 329–39PubMedCrossRef

111.

Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69: 361–74

112.

Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44: 1850–4PubMedCrossRef

113.

McGinnis MR, Pasarell L, Sutton DA, et al. Invitroevaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41: 1832–4PubMed

114.

Espinel-Ingroff A. Invitroactivity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198–202PubMed

115.

Chariyalertsak S, Sirisanthana T, Saengwonloey O, et al. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994–1998: regional variation and temporal trends. Clin Infect Dis 2001 Mar 15; 32(6): 955–62PubMedCrossRef

116.

Piehl MR, Kaplan RL, Haber MH. Disseminated penicilliosis in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med 1988; 112: 1262–4PubMed

117.

Hilmarsdottir I, Meynard JL, Rogeaux O, et al. Disseminated Penicilliummameffeiinfection associated with human immunodeficiency virus: a report of two cases and a review of 35 published cases. J Acquir Immune Defic Syndr 1993 May; 6(5): 466–71PubMedCrossRef

118.

Hung CC, Chen MY, Hsieh SM, et al. Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy. AIDS 2002; 16: 672–3PubMedCrossRef

119.

Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillusin respiratory specimens from persons with HIV disease: Pulmonary Complications of HIV Infection Study Group. Chest 1998; 114: 131–7PubMedCrossRef

120.

Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Clin Infect Dis 2000; 31: 1253–7PubMedCrossRef

121.

Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by aspergillus. Clin Infect Dis 2000; 30: 696–709PubMedCrossRef

122.

Klapholz A, Salomon N, Perlman DC, et al. Aspergillosis in the acquired immunodeficiency syndrome. Chest 1991; 100: 1614–8PubMedCrossRef

123.

Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 Jan 22; 34(5): 563–71PubMedCrossRef

124.

Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–15PubMedCrossRef

125.

Chapman SW, Bradsher Jr RW, Campbell Jr GD, et al. Practice guidelines for the management of patients with blastomycosis. Clin Infect Dis 2000; 30: 679–83PubMedCrossRef

126.

Goldani LZ, Sugar AM. Paracoccidioidomycosis and AIDS: an overview. Clin Infect Dis 1995; 21(5): 1275–81PubMedCrossRef

127.

Walsh TJ, Gonzalez C, Roilides E, et al. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin Infect Dis 1995; 20: 900–6PubMedCrossRef

128.

Launay O, Lortholary O, Bouges-Michel C, et al. Candidemia: a nosocomial complication in adults with late-stage AIDS. Clin Infect Dis 1998; 26: 1134–41PubMedCrossRef

129.

Arthur G, Nduba VN, Kariuki SM, et al. Trends in bloodstream infections among human immunodeficiency virus-infected adults admitted to a hospital in Nairobi, Kenya, during the last decade. Clin Infect Dis 2001 Jul 15; 33(2): 248–56PubMedCrossRef

130.

al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis 1998; 26: 1403–6PubMedCrossRef

131.

Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis: for the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 684–7CrossRef

132.

Carvalho MT, de Castro AP, Baby C, et al. Disseminated cutaneous sporotrichosis in a patient with AIDS: report of a case. Rev Soc Bras Med Trop 2002; 35: 655–9PubMedCrossRef

Title: Mucosal and Systemic Fungal Infections in Patients with AIDS
Prophylaxis and Treatment
Author: Dr Markus Ruhnke, Med
Publication date: 01-06-2004
Publisher: Springer International Publishing
Published in: Drugs / Issue 11/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464110-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mucosal and Systemic Fungal Infections in Patients with AIDS

Prophylaxis and Treatment

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Zoledronic Acid

The Authors’ Reply

Letrozole

Medical Lipid-Regulating Therapy

Valdecoxib

Evolving Strategies for Insulin Delivery and Therapy